AJA Pharmaceutical Industries Co. Ltd.

ajapharma.com

AJA Pharma has its own state of-the-art manufacturing plant, located in Hail Industrial City of Saudi Arabia. The plant is aimed to provide latest & highest standards of manufacturing services across the region. AJA Pharmaceuticals plant is capable to produce a wide range of pharmaceutical products in various finished dosage forms, thereby catering to the Contract manufacturing needs of our partners globally. We aim in AJA Pharma to enter into collaborations to co-Develop, co-Manufacture, co-Market and to widely sell and distribute carefully selected range of products as well as under license production projects with technology transfer; relying on the huge capabilities, highest quality and unique technologies we have in AJA Pharma Plant including the processing of lyophilized injectables to satisfy the ever-increasing market demands in our region and across the Globe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

AQUESTIVE THERAPEUTICS EXPANDS LICENSE AND SUPPLY AGREEMENT WITH PHARMANOVIA FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO ADDITIONAL GLOBAL MARKETS

Globenewswire | March 30, 2023

news image

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Libervant™ Buccal Film to cover the rest ...

Read More

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

news image

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

news image

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Read More

Pharma Tech

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene Corporation Limited | June 27, 2022

news image

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizum...

Read More
news image

Business Insights, PHARMACY MARKET

AQUESTIVE THERAPEUTICS EXPANDS LICENSE AND SUPPLY AGREEMENT WITH PHARMANOVIA FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO ADDITIONAL GLOBAL MARKETS

Globenewswire | March 30, 2023

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Libervant™ Buccal Film to cover the rest ...

Read More
news image

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More
news image

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Read More
news image

Pharma Tech

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene Corporation Limited | June 27, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizum...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us